Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
norethindrone acetate + ethinyl estradiol + ferrous fumarate
- Development stage
- Unknown
- Lead developer
- Warner Chilcott
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
norethindrone acetate + ethinyl estradiol + ferrous fumarate is a combined oral contraceptive (COC) formulation. It contains norethindrone acetate (a progestin) and ethinyl estradiol (a synthetic estrogen), often packaged with ferrous fumarate (iron) tablets to be taken during the hormone-free interval to maintain the daily dosing habit and provide iron supplementation. While its primary indication is the prevention of pregnancy, researchers at Cedars-Sinai Medical Center have investigated its use in female athletes to protect against anterior cruciate ligament (ACL) injuries. The hypothesized mechanism for this protective effect is the stabilization of hormonal fluctuations—specifically relaxin—which can increase joint laxity and injury risk during certain phases of the menstrual cycle.
- Brand names
- Loestrin FeMicrogestin FeJunel FeLarin FeGildess FeTaytullaMinastrin 24 FeMinastrin24 FeMinastrin-24 Fe
- Other names
- norethindrone acetate + ethinyl estradiol + ironnorethindrone acetate/ethinyl estradiol/ferrous fumarate
02
Targets
PR (Progesterone receptor)ESR1 (ERα)ESR2 (ERβ)
Beyond the preview
Go deeper on norethindrone acetate + ethinyl estradiol + ferrous fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on norethindrone acetate + ethinyl estradiol + ferrous fumarate.